CRISPR sheds light on rare pediatric bone marrow failure syndrome

July 27, 2017, Washington University School of Medicine
Chromosomes (blue) have protective end caps called telomeres that help them maintain stability. In this image, the telomeres (green) are abnormally short, which leads to DNA damage that accrues over time. Using the gene editing technology CRISPR, scientists at Washington University School of Medicine in St. Louis have shed light on a rare syndrome that causes children to lose the ability to manufacture vital blood cells. The syndrome, dyskeratosis congenita, is characterized by shortened telomeres. Credit: Marquet Minor

Using the gene editing technology CRISPR, scientists have shed light on a rare, sometimes fatal syndrome that causes children to gradually lose the ability to manufacture vital blood cells.

The research, at Washington University School of Medicine in St. Louis, suggests new lines of investigation into how to treat this condition—dyskeratosis congenita—which is characterized by shortened telomeres. Telomeres, the protective caps on the ends of chromosomes, help maintain DNA stability. Short telomeres lead to progressive DNA damage that accumulates over time.

The study appears July 27 in the journal Stem Cell Reports.

"Lengthening telomeres seems like a logical way to help these patients, but it could possibly come with its own set of problems," said senior author Luis F.Z. Batista, PhD, an assistant professor of medicine. "We would worry about encouraging cancer formation, for example, as high levels of the protein that lengthens telomeres—telomerase—are commonly found with cancer. But if we could find a way to block the signaling pathways that short telomeres activate—that specifically lead to the problems in —it could allow these patients to continue making ."

Children with dyskeratosis congenita experience progressive , eventually losing the ability to make , and platelets. They are also at high risk of leukemia. Severity of the condition varies widely, but those with severe forms often die of bone marrow failure in young adulthood. The damage of short telomeres is most apparent in rapidly dividing cell types, such as those in the skin, nail beds, mucous membranes and blood. Early signs of the disease include misshapen fingernails, abnormal skin pigmentation and white patches in the mouth.

Because the disease is challenging to study in mice—as mice deficient in telomerase don't fully experience bone marrow failure—the researchers used CRISPR to edit into human two mutations associated with the disease. The researchers then showed that these reproduced the telomere-shortening defect seen in patients with the disorder. Batista and co-senior author Christopher M. Sturgeon, PhD, an assistant professor of medicine, observed that these methods represent a novel and accurate human model of the disorder.

With this model, the scientists further showed how the defect leads to the gradual loss of blood cell formation from human embryonic stem cells and, importantly, how blocking the downstream effects of the defect can reverse this loss, leading to normal production of blood cells. Blocking this signaling pathway did not lengthen telomeres or stop their shortening, but allowed the manufacturing of different types of blood cells to continue, according to the study.

The researchers also teased out an important nuance in the detrimental effect of short telomeres during early development. Using an approach that mimics early embryonic development, they found that the defect did not prevent the formation and function of blood cells produced during the first month of gestation that allow an embryo to fuel its rapidly growing oxygen needs. Rather, the defect arrested the production of adult-like blood cell progenitors, such as red blood cells that carry oxygen or white blood cells that fight infection.

"This was tremendously interesting from a developmental biology perspective as well as from a disease modeling perspective," Sturgeon said. "We now have a platform to really dig deeper into understanding the mechanisms behind some forms of bone marrow failure."

Interestingly, the researchers implicated high levels of a protein called p53 as one of the signals that leads to the drop in adult-like cell formation. The p53 protein is usually considered protective of DNA.

"P53 is thought of as a guardian of the genome," Batista said. "Mutations that disable p53 are associated with different types of cancer. Because of this we would not consider directly trying to block p53 in these patients. But what this study provides is proof-of-concept that this pathway is involved in this response. So we now are looking for ways to block the pathway further downstream without necessarily blocking p53 directly."

Batista and Sturgeon recently received a grant from the Department of Defense to investigate these pathways. The strategy used in this study could be relevant for other bone marrow failure syndromes, such as Fanconi anemia and aplastic anemia, which also involve DNA damage accrual caused by different mutations.

Explore further: Gene mutation discovered in blood disorder

More information: Fok WC, de Oliveira Niero EL, Dege C, Brenner KA, Sturgeon CM, Batista LFZ. p53 mediates failure of human definitive hematopoiesis in dyskeratosis congenita. Stem Cell Reports. July 27, 2017.

Related Stories

Gene mutation discovered in blood disorder

September 23, 2014
An international team of scientists has identified a gene mutation that causes aplastic anemia, a serious blood disorder in which the bone marrow fails to produce normal amounts of blood cells. Studying a family in which ...

Researchers fight aplastic anemia using a therapy designed to delay ageing

February 24, 2016
Aplastic anaemia is a rare, and potentially fatal, disease of the blood, by which the bone marrow is unable to generate blood cells at the appropriate pace. Many forms of aplastic anaemia share an important link with the ...

Team creates a unique mouse model for the study of aplastic anaemia

August 29, 2012
Aplastic anaemia is characterised by a reduction in the number of the bone marrow cells that go on to form the different cell types present in blood (essentially red blood cells, white blood cells and platelets). In most ...

New test more effective at predicting survival in blood cancer patients

May 10, 2017
Technology that can detect the length of small DNA structures in cancer cells could hold the key to predicting the outcome of patients with two different types of blood cancer. The test, used in conjunction with current methods, ...

Chinese herbal treatment shows signs of effectiveness in bone marrow recovery

December 15, 2016
UCLA researchers have found that a Chinese herbal regimen called TSY-1 (Tianshengyuan-1) increased telomerase activity in normal blood cells but decreased it in cancer cells. Telomerase is an enzyme responsible for the production ...

Recommended for you

AI matched, outperformed radiologists in screening X-rays for certain diseases

November 21, 2018
In a matter of seconds, a new algorithm read chest X-rays for 14 pathologies, performing as well as radiologists in most cases, a Stanford-led study says.

Machine learning can be used to predict which patients require emergency admission

November 20, 2018
Machine learning—a field of artificial intelligence that uses statistical techniques to enable computer systems to 'learn' from data—can be used to analyse electronic health records and predict the risk of emergency hospital ...

Researchers stop 'sneaky' cancer cells in their tracks

November 20, 2018
A new study by University of Minnesota biomedical engineers shows how they stopped cancer cells from moving and spreading, even when the cells changed their movements. The discovery could have a major impact on millions of ...

A Trojan horse delivery method for miRNA-enriched extracellular vesicles

November 20, 2018
A method for large-scale production of extracellular vesicles enriched with specific microRNAs (miRNAs) has been developed in the Wake Forest Institute for Regenerative Medicine (WFIRM) labs, offering a manufacturing standardization ...

Researchers hope to be able to replace dysfunctional brain cells

November 20, 2018
A new study by researchers at Karolinska Institutet supports the theory that replacement of dysfunctional immune cells in the brain has therapeutic potential for neurodegenerative diseases like ALS and Alzheimer's disease. ...

RNAi therapy mitigates preeclampsia symptoms

November 19, 2018
A collaboration of scientists from the University of Massachusetts Medical School, Beth Israel Deaconess Medical Center and Western Sydney University, have shown that an innovative new type of therapy using small interfering ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.